Why is Monopar Therapeutics stock up today?

Traders Union
All News
Financial News
Monopar Therapeutics rises 3.98% today

Highlights

Monopar Therapeutics maintains a bullish short- and medium-term trend, approaching important long-term resistance near $65.00.
Momentum is mixed, with MACD and intraday signals favoring buyers, while weekly indicators and ADX suggest caution.
The stock is expected to consolidate in a $62.84–$65.08 range over the next week unless a breakout or breakdown occurs.

Anton Kharitonov, expert at Traders Union, notes that MNPR’s technicals show near-term bullishness but warns of fading momentum as key resistances approach. He highlights that supportive signals from indicators are offset by the lack of news drivers and mixed short-term oscillators. The expert is cautious about the overbought signs seen in BBP and some oscillators. Absence of fresh institutional or news catalysts adds to his skepticism regarding further upside. "Without fresh catalysts, I see a high risk of consolidation or even reversal if $65.00 fails to break convincingly."

Viktoras Karapetjanc, expert at Traders Union, sees a constructive setup for MNPR as price holds above key moving averages. He believes bullish structure remains intact with dynamic support from Ichimoku Kijun likely to attract buyers. The analyst notes that despite the absence of news, the technicals suggest further growth potential if $65.00 is surpassed. "The market offers multiple setups here, and I expect bullish momentum to drive a test of higher levels this week."

Mixed short-term signals as support levels and intraday bulls emerge

The nearest dynamic support is seen at the Ichimoku Kijun level ($58.99), with further resistance expected at the round level near $65.00 if bullish momentum continues. MACD is in buy territory, and the ADX shows a neutral trend, suggesting lukewarm bullish momentum. The RSI setup is constructive and not overbought; however, Stochastic RSI and CCI indicate mixed short-term signals with some overbought and oversold pockets. BBP highlights intraday buyer dominance and an overbought bias, while the Awesome Oscillator also supports intraday bullishness. The stock opened nearly flat and currently trades mid-range, with intraday volatility at 9.88% and a positive session tone as price action holds above the open.

Earlier, analysts noted that Monopar Therapeutics was likely to experience continued sideways action amid mixed short-term momentum and unresolved resistance. The latest price surge and bullish technical developments suggest upward momentum may be building, making a clear break above $65.00 a pivotal level for traders to monitor in the coming days.

Source of Data: MNPR Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.